Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 13, 2006

Neurotechnology Industry Organization Launched

  • More than 20 leading pharmaceutical, medical device, and diagnostic companies, along with major academic brain research centers and patient advocacy groups, have joined to form a new trade association called the Neurotechnology Industry Organization (NIO). Based in San Francisco, NIO is a nonprofit group created to accelerate the development of treatments and cures for central nervous system diseases.

    “Despite the clear need and significant market opportunity, neurotechnology companies face a host of issues that stifle innovation, growth, and rapid delivery of effective therapies,” says Zack Lynch, founder and executive director of NIO. “NIO will provide a collective voice for commercial neuroscience organizations to address these issues.”

    Founding member organizations include: Acumen Pharmaceuticals, Amarin, Brain Resource, Ceregene, Cyberkinetics Neurotechnology Systems, NeuroPace, NeuroNova, Sound Pharmaceuticals, Targacept, and United Therapeutics.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »